The arrival of powerful new drugs for obesity has reshaped the pharmaceutical industry, transforming Eli Lilly and Novo Nordisk into the sector’s most valuable companies and sending others scrambling to catch up.
Analysts predict that so-called GLP-1 drugs like Lilly’s Zepbound and Novo’s Ozempic will become some of the most lucrative products ever sold. Their benefits appear to extend beyond weight loss and blood sugar control, too, raising the possibility they may also change how obesity is treated.
